Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
67°
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Merck & Co
(NY:
MRK
)
130.52
+1.07 (+0.83%)
Official Closing Price
Updated: 7:00 PM EDT, Jun 6, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Merck & Co
< Previous
1
2
...
6
7
8
9
10
11
12
13
14
...
17
18
Next >
LYNPARZA® (olaparib) Approved in China as First-Line Maintenance Treatment With Bevacizumab for Homologous Recombination Deficient (HRD)-Positive Advanced Ovarian Cancer
September 22, 2022
From
Merck & Co., Inc.
Via
Business Wire
U.S. District Court Rules In Favor of Merck in Sitagliptin Phosphate Patent Lawsuit
September 22, 2022
From
Merck & Co., Inc. Merck
Via
Business Wire
Merck to Initiate New Phase 3 Clinical Program with Lower Dose of Daily Oral Islatravir in Combination with Doravirine for Treatment of People with HIV-1 Infection
September 20, 2022
From
Merck & Co., Inc.
Via
Business Wire
Merck Receives Positive CHMP Opinion for VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) in Infants and Children
September 16, 2022
From
Merck & Co., Inc.
Via
Business Wire
Eisai and Merck & Co., Inc. Present Results from Phase 3 LEAP-002 Trial Evaluating LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma
September 12, 2022
Via
JCN Newswire
Seagen, Astellas and Merck Announce Results of Clinical Trial Investigating PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) and PADCEV as Monotherapy in First-Line Advanced Urothelial Cancer
September 12, 2022
From
Seagen Inc.
Via
Business Wire
Five-Year Data for Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy Showed Sustained Survival Benefit Versus Chemotherapy Alone in Two Studies for Metastatic Non-Small Cell Lung Cancer (NSCLC)
September 11, 2022
From
Merck & Co., Inc.
Via
Business Wire
Merck and Eisai Present Results From Phase 3 LEAP-002 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma
September 10, 2022
From
Merck & Co., Inc.
Via
Business Wire
LYNPARZA® (olaparib) in Combination With Bevacizumab, and as Monotherapy, Demonstrates Clinically Meaningful Long-Term Survival in Certain Patients With First-Line Advanced Ovarian Cancer in Exploratory Analyses of Two Phase 3 Trials
September 09, 2022
From
Merck & Co., Inc.
Via
Business Wire
Merck Foundation Launches $20 Million Initiative to Advance Equity in U.S. Cancer Care
September 08, 2022
From
Merck Foundation
Via
Business Wire
Merck to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
September 06, 2022
From
Merck & Co., Inc.
Via
Business Wire
Monkeypox vaccine and research related stocks taking center stage (VRAX,GOVX,TNXP,APDN)
September 02, 2022
Via
AB Newswire
Exposures
COVID-19
Merck Reports Strong Progress in ESG Focus Areas
August 30, 2022
From
Merck & Co., Inc.
Via
Business Wire
Merck to Present New Data at ESMO 2022 Congress From Its Broad Oncology Portfolio and Promising Pipeline, Demonstrating Commitment to Improving Long-Term Survival in Multiple Types of Cancer
August 29, 2022
From
Merck & Co., Inc.
Via
Business Wire
LYNPARZA® (olaparib) Approved in Japan as Adjuvant Treatment for Patients With BRCA-Mutated, HER2-Negative High Recurrent Risk Breast Cancer
August 25, 2022
From
Merck & Co., Inc.
Via
Business Wire
Merck Receives Fast Track Designation from the U.S. FDA for MK-2060, an Investigational Anticoagulant Therapy
August 23, 2022
From
Merck & Co., Inc.
Via
Business Wire
FDA Accepts Submission of Supplemental New Drug Application for LYNPARZA® (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone for Patients With Metastatic Castration-Resistant Prostate Cancer and Grants Priority Review
August 16, 2022
From
Merck & Co., Inc.
Via
Business Wire
Merck and Orna Therapeutics Collaborate to Advance Orna’s Next Generation of RNA Technology
August 16, 2022
From
Merck & Co., Inc.
Via
Business Wire
NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) Pioneering Innovative Hypertension Treatments
August 11, 2022
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
The Power of Science to Stop a Killer
August 08, 2022
Via
Investor Brand Network
The Power of Science to Stop a Killer
August 08, 2022
NetworkNewsWire Editorial Coverage New York, NY – August 8, 2022 – Nearly half of all American adults suffer from hypertension (high blood pressure), often referred to as a silent killer. More than 114...
Via
FinancialNewsMedia
LYNPARZA® (olaparib) Approved in the EU as Adjuvant Treatment for Patients With Germline BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer
August 04, 2022
From
Merck & Co., Inc.
Via
Business Wire
3 Pharma Stocks' Post-Earnings Price Moves
August 04, 2022
The health care sector is participating in the S&P's nascent rally, but pharmaceuticals AbbVie, Merck and Pfizer are holding up well relative to the market.
Via
MarketBeat
Topics
ETFs
Stocks
Exposures
US Equities
Merck and Eisai Provide Update on Phase 3 LEAP-002 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma
August 03, 2022
From
Merck & Co., Inc.
Via
Business Wire
Merck Provides Update on Phase 3 KEYNOTE-921 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer
August 03, 2022
From
Merck & Co., Inc.
Via
Business Wire
Merck Announces Second-Quarter 2022 Financial Results
July 28, 2022
From
Merck & Co., Inc.
Via
Business Wire
Merck Announces Fourth-Quarter 2022 Dividend
July 26, 2022
From
Merck & Co., Inc.
Via
Business Wire
Three Watchlist Stocks to Capitalize on Sector Rotation
July 23, 2022
Sector rotation is a common market event based on the theory that economies move in cycles. Here are three stocks, one apiece, from sectors that institutions are rotating into.
Via
MarketBeat
Topics
Economy
Exposures
Interest Rates
Merck Provides Update on Phase 3 KEYNOTE-412 Trial in Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma
July 20, 2022
From
Merck & Co., Inc.
Via
Business Wire
Merck and Orion Announce Global Collaboration for the Development and Commercialization of ODM-208, an Investigational Steroid Synthesis Inhibitor for the Treatment of Metastatic Castration-Resistant Prostate Cancer
July 13, 2022
From
Merck & Co., Inc.
Via
Business Wire
< Previous
1
2
...
6
7
8
9
10
11
12
13
14
...
17
18
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.